A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants
A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants
Statut
Status :
Active not recruiting
Type d'étude
Phase I
Age Min.
18
Ans
Age Max.
65
Ans
Genre
Tous
Aire thérapeutique :
Oncologie
Maladie :
Mélanome
Traitement :
Binimetinib (MEKTOVI®)
Phase :
Phase I
Date de début de l'étude :
03 Septembre 2021
End date :
19 Novembre 2021
Identifiant de l'essai :
W00074 CI 101
Identifiant EudraCT/CTIS :
2022-000610-34
Identifiant CT.gov :
NCT05103891
Envoyer par email